BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 21093232)

  • 1. Plasminogen activator inhibitor 1 and visceral obesity during pronounced weight loss after bariatric surgery.
    Tschoner A; Sturm W; Engl J; Kaser S; Laimer M; Laimer E; Klaus A; Patsch JR; Ebenbichler CF
    Nutr Metab Cardiovasc Dis; 2012 Apr; 22(4):340-6. PubMed ID: 21093232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subcutaneous abdominal, but not femoral fat expression of plasminogen activator inhibitor-1 (PAI-1) is related to plasma PAI-1 levels and insulin resistance and decreases after weight loss.
    Mavri A; Alessi MC; Bastelica D; Geel-Georgelin O; Fina F; Sentocnik JT; Stegnar M; Juhan-Vague I
    Diabetologia; 2001 Nov; 44(11):2025-31. PubMed ID: 11719834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between visceral fat and PAI-1 in overweight men and women before and after weight loss.
    Kockx M; Leenen R; Seidell J; Princen HM; Kooistra T
    Thromb Haemost; 1999 Nov; 82(5):1490-6. PubMed ID: 10595643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retinol-binding protein 4, visceral fat, and the metabolic syndrome: effects of weight loss.
    Tschoner A; Sturm W; Engl J; Kaser S; Laimer M; Laimer E; Weiss H; Patsch JR; Ebenbichler CF
    Obesity (Silver Spring); 2008 Nov; 16(11):2439-44. PubMed ID: 18719670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of weight loss on serum pigment epithelium-derived factor levels.
    Tschoner A; Sturm W; Ress C; Engl J; Kaser S; Laimer M; Laimer E; Klaus A; Tilg H; Patsch JR; Ebenbichler CF
    Eur J Clin Invest; 2011 Sep; 41(9):937-42. PubMed ID: 21314826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Visceral fat is a determinant of PAI-1 activity in diabetic and non-diabetic overweight and obese women.
    Mertens I; Van der Planken M; Corthouts B; Wauters M; Peiffer F; De Leeuw I; Van Gaal L
    Horm Metab Res; 2001 Oct; 33(10):602-7. PubMed ID: 11607880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epicardial fat thickness: relationship with plasma visfatin and plasminogen activator inhibitor-1 levels in visceral obesity.
    Malavazos AE; Ermetici F; Cereda E; Coman C; Locati M; Morricone L; Corsi MM; Ambrosi B
    Nutr Metab Cardiovasc Dis; 2008 Oct; 18(8):523-30. PubMed ID: 18083357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inverse relationship between plasminogen activator inhibitor-I activity and adiponectin in overweight and obese women. Interrelationship with visceral adipose tissue, insulin resistance, HDL-chol and inflammation.
    Mertens I; Ballaux D; Funahashi T; Matsuzawa Y; Van der Planken M; Verrijken A; Ruige JB; Van Gaal LF
    Thromb Haemost; 2005 Dec; 94(6):1190-5. PubMed ID: 16411393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human visceral adipose tissue and the plasminogen activator inhibitor type 1.
    Lindeman JH; Pijl H; Toet K; Eilers PH; van Ramshorst B; Buijs MM; van Bockel JH; Kooistra T
    Int J Obes (Lond); 2007 Nov; 31(11):1671-9. PubMed ID: 17471294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasminogen activator inhibitor type 1 (PAI-1) in plasma and adipose tissue in HIV-associated lipodystrophy syndrome. Implications of adipokines.
    He G; Andersen O; Haugaard SB; Lihn AS; Pedersen SB; Madsbad S; Richelsen B
    Eur J Clin Invest; 2005 Sep; 35(9):583-90. PubMed ID: 16128865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma PAI-1 levels in obese children--effect of weight loss and influence of PAI-1 promoter 4G/5G genotype.
    Estellés A; Dalmau J; Falcó C; Berbel O; Castelló R; España F; Aznar J
    Thromb Haemost; 2001 Aug; 86(2):647-52. PubMed ID: 11522017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of bariatric surgery on both functional and structural measures of premature atherosclerosis.
    Sturm W; Tschoner A; Engl J; Kaser S; Laimer M; Ciardi C; Klaus A; Weiss H; Sandhofer A; Patsch JR; Ebenbichler CF
    Eur Heart J; 2009 Aug; 30(16):2038-43. PubMed ID: 19502233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different metabolic correlations of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 in non-obese type 2 diabetic patients.
    Kitagawa N; Yano Y; Gabazza EC; Bruno NE; Araki R; Matsumoto K; Katsuki A; Hori Y; Nakatani K; Taguchi O; Sumida Y; Suzuki K; Adachi Y
    Diabetes Res Clin Pract; 2006 Aug; 73(2):150-7. PubMed ID: 16458385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Central obesity, the metabolic syndrome, and plasminogen activator inhibitor-1 in young adults.
    Appel SJ; Harrell JS; Davenport ML
    J Am Acad Nurse Pract; 2005 Dec; 17(12):535-41. PubMed ID: 16293162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals.
    Eriksson P; Reynisdottir S; Lönnqvist F; Stemme V; Hamsten A; Arner P
    Diabetologia; 1998 Jan; 41(1):65-71. PubMed ID: 9498632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between plasminogen activator inhibitor-1 antigen, leptin, and fat mass in obese children and adolescents.
    Sudi KM; Gallistl S; Weinhandl G; Muntean W; Borkenstein MH
    Metabolism; 2000 Jul; 49(7):890-5. PubMed ID: 10910001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is visceral adipose tissue a determinant of von Willebrand factor in overweight and obese premenopausal women?
    Mertens I; Van der Planken M; Corthouts B; Van Gaal LF
    Metabolism; 2006 May; 55(5):650-5. PubMed ID: 16631442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Body fat distribution: its characteristics and relationship to cardiovascular risk factors in obese Chinese].
    Ran XW; Li XS; Tong NW; Li QF; Tang BD; Li XJ
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Sep; 35(5):699-703. PubMed ID: 15460424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in plasminogen activator inhibitor 1 in subcutaneous versus omental adipose tissue in non-obese and obese subjects.
    He G; Pedersen SB; Bruun JM; Lihn AS; Jensen PF; Richelsen B
    Horm Metab Res; 2003 Mar; 35(3):178-82. PubMed ID: 12734779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term treatment with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone-deficient adults.
    Johansson JO; Landin K; Johannsson G; Tengborn L; Bengtsson BA
    Thromb Haemost; 1996 Sep; 76(3):422-8. PubMed ID: 8883281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.